

## Pluvicto<sup>®</sup> (lutetium Lu 177 vipivotide tetraxetan) – Expanded indication

- On March 28, 2025, <u>Novartis announced</u> the FDA approval of <u>Pluvicto (lutetium Lu 177 vipivotide tetraxetan)</u>, for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy.
  - Pluvicto was previously approved for this indication in patients who have been treated with ARPI therapy and have received prior taxane-based chemotherapy. This approval expands the use of Pluvicto for earlier use before chemotherapy.
- The approval of Pluvicto for the expanded indication was based on PSMAfore, a randomized, open-label study in 468 patients with progressive, PSMA-positive mCRPC. Patients were randomized to Pluvicto every 6 weeks for 6 doses or a change in ARPI. The major outcome measure was radiographic progression-free survival (rPFS). Additional efficacy measures were overall survival (OS) and overall response rate (ORR).
  - Median rPFS was 9.3 months with Pluvicto vs. 5.6 months with ARPI (hazard ratio 0.41, 95% CI: 0.29, 0.56; p < 0.0001).</li>
  - The difference in median OS between the two groups was not significant.
  - The ORR was 49% (95% CI: 37, 61) with Pluvicto vs. 14% (95% CI: 7, 24) with ARPI.
- The recommended Pluvicto dosage is 7.4 GBq (200 mCi) intravenously every 6 weeks for 6 doses, or until disease progression, or unacceptable toxicity.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.